First Patient in India Treated at Indian Spinal Injuries Centre, New Delhi
Surgical Robotics Market in India is Predicted to Grow Remarkably
Mazor X Stealth Edition™Will Enable Doctors to Plan Their Surgery, Provide Assistance to Execute the Plan Precisely and Visualize the Progress in Real-Time.
MUMBAI / CHENNAI, India – November 27, 2019–India Medtronic Private Limited, wholly-owned subsidiary ofMedtronic plc(NYSE:MDT), today announced the launch of the Mazor X Stealth Edition™ that offers a fully-integrated procedural solution for surgical planning, workflow, execution and confirmation of spine surgeries. Surgeons at Indian Spinal Injuries Centre, New Delhi, have successfully performed the first minimally invasive spine surgery in India using the Mazor X Stealth Edition Robotic-Assisted Spine Surgery System.
The global surgical robotics market has a vast potential, and it is expected to grow to US$9.3 billion by 2025 from US$4.9 billion back in 2016 with a CAGR of 11.4%1. In India, with a rapidly growing senior population, the spine surgery rate is expected to rise. The Surgical Robotics Market in India is predicted to witness a remarkable increase from US$129.9 million in 2016 to US$372.5 million in 2025, growing at a CAGR of 19.2%.1
“Minimally-invasive spinal procedures with their smaller incisions can pose a challenge to surgeons due to the limited view of the patient’s anatomy. The combination of robotics and navigation provides an opportunity for not only procedural benefits but also the potential for clinical efficiency and improvement in patient outcomes,” said Dr. H.S. Chhabra, medical director, Indian Spinal Injuries Centre, New Delhi.“We can now perform the same spinal surgery with precision as planned along with the ability to confirm through navigation that the implant is going in the location as it was intended to.”
“We believe technology has the power to improve lives. That’s why we are continually innovating novel products and procedural solutions in the area of minimally invasive therapies; to improve the quality of life for all patients. We are bringing a myriad of new technologies to India to improve access to the best treatment options for patients,” said Madan Krishnan, vice president and managing director, India Medtronic Pvt Ltd.“This year being the 40th year for Medtronic in India, we are happy to demonstrate our commitment to transforming healthcare in India with renewed vigour by launching the Mazor X Stealth Edition Robotic-assisted Spine Surgery System.”
between Medtronic and the recently acquired Mazor Robotics, the Mazor X Stealth
Edition seamlessly incorporates Stealth™ software technology into the Mazor X™robotic-assisted
surgery platform.It is a revolutionary new technology that uses cutting-edge
software to plan the surgical procedure, then uses a robotic arm to guide
implants and instruments through the steps of the surgical process with
precision, while simultaneously using real-time imaging feedback to ensure the
plan is being carried out as desired. The Mazor X Stealth Edition operates on
three principals: first, the surgeon can plan and visualize the surgery
beforehand to study multiple levels and the entire process; second, the robotic
guidance system will be an extension of the doctor during the process and is
intended to enable execution with precision; and third, the doctor can
visualize progress in real-time.
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.